Cardio-Oncology is affiliated with the International Cardio-Oncology Society (ICOS).
Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy
25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a de...